Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies
Cancer Letters · 2024-12 · 607 · 217309
DOI: 10.1016/j.canlet.2024.217309 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-12. Verfasst von Xing-Duo Dong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily G, Member 2, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 84 Literaturangaben.
Abstract (Originalsprache)
Overexpression of ATP-binding cassette (ABC) transporters, particularly ABCB1 and ABCG2, strongly correlates with multidrug resistance (MDR), rendering cancer chemotherapy ineffective. Exploration and identification of novel inhibitors targeting ABCB1 and ABCG2 are necessary to overcome the related MDR. Mobocertinib is an approved EGFR/HER2 inhibitor for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. This study demonstrates that mobocertinib can potentially reverse ABCB1- and ABCG2-mediated MDR. Our findings indicate a strong interaction between mobocertinib and these two proteins, supported by its high binding affinity with ABCB1 and ABCG2 models. Through inhibiting the drug efflux function of ABCB1 and ABCG2, mobocertinib facilitates substrate drugs accumulation, thereby re-sensitizing substrate drugs in drug-resistant cancer cells. Additionally, mobocertinib inhibited the ATPase activity of ABCB1 and ABCG2 without changing the expression levels or subcellular localization. In the tumor-bearing mouse model, mobocertinib boosted the antitumor effect of paclitaxel and topotecan, resulting in tumor regression. In summary, our study uncovers a novel potential for repurposing mobocertinib as a dual inhibitor of ABCB1 and ABCG2, and suggests the combination of mobocertinib with substrate drugs as a strategy to counteract MDR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA.
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA; Department of Thyroid and Breast Surgery, Shenzhen Hospital of Southern Medical University,…
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA; Guangdong Provincial Key Laboratory of Digestive Cancer Research, Digestive Diseases Center,…
- Department of Thoracic Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100069, China. Electronic address: guohuiqin@mail.ccmu.edu.cn.
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA. Electronic address: chenz@stjohns.edu.
Zitieren
APA
Dong, X. D., Zhang, M., Teng, Q. X., Lei, Z. N., Cai, C. Y., Wang, J. Q., Wu, Z. X., Yang, Y., Chen, X., Guo, H., & Chen, Z. S. (2024). Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies. Cancer Letters, 607, 217309. https://doi.org/10.1016/j.canlet.2024.217309
Vancouver
Dong XD, Zhang M, Teng QX, Lei ZN, Cai CY, Wang JQ, et al. Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies. Cancer Letters. 2024;607:217309. doi:10.1016/j.canlet.2024.217309
BibTeX
@article{Dong2024,
author = {Dong, Xing-Duo and Zhang, Meng and Teng, Qiu-Xu and Lei, Zi-Ning and Cai, Chao-Yun and Wang, Jing-Quan and Wu, Zhuo-Xun and Yang, Yuqi and Chen, Xiang and Guo, Huiqin and Chen, Zhe-Sheng},
title = {Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies},
journal = {Cancer Letters},
year = {2024},
volume = {607},
pages = {217309},
doi = {10.1016/j.canlet.2024.217309}
}
EUVIMED